Skip to main content
BCDA
NASDAQ Life Sciences

BioCardia的III期CardiAMP HF试验报告了阳性超声心动图结果，显示减少的室性重塑

feedReported by Wiseek News
Sentiment info
Positive
Importance info
9
Price
$1.37
Mkt Cap
$14.327M
52W Low
$1
52W High
$3.2
Market data snapshot near publication time

summarizeSummary

BioCardia宣布其III期CardiAMP HF试验的超声心动图结果为阳性，表明治疗患者的病理性左心室重塑减少。数据在THT上发表，显示了左心室末舒张和末收缩容积的有利差异，并在NTproBNP升高的患者亚组中显示出统计学显著的改善。这对于BioCardia来说是一个高度重要的发展，BioCardia是一家临床阶段的生物技术公司，阳性的III期数据显著降低了其主要产品候选物的风险，并使其更接近潜在的监管审批。结果与之前观察到的减少主要不良心血管事件和改善生活质量的趋势一致。投资者现在将密切关注完整数据发布、随后的监管申报以及CardiAMP HF的潜在商业化途径。

在该公告发布时，BCDA的交易价格为$1.37，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1432.7万。 52周交易区间为$1.00至$3.20。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed BCDA - Latest Insights

BCDA
Apr 28, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
BioCardia Secures Key Japanese Patent for Heart3D™ Imaging Software
Sentiment: Positive
View Wiseek Article
BCDA
Apr 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
BioCardia's CardiAMP Cell Therapy Nears Japan Market Clearance with Positive PMDA Consultation
Sentiment: Positive
View Wiseek Article
BCDA
Apr 15, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
Nasdaq Notifies BioCardia of Listing Non-Compliance, Citing Equity Shortfall
Sentiment: Negative
View Wiseek Article
BCDA
Apr 15, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
BioCardia Receives Formal Nasdaq Delisting Non-Compliance Notice
Sentiment: Negative
View Wiseek Article
BCDA
Apr 02, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
BioCardia Submits CardiAMP HF Data to FDA, Seeks Accelerated Approval Pathway Meeting
Sentiment: Positive
View Wiseek Article
BCDA
Mar 24, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
BioCardia Discloses Going Concern Doubt and Nasdaq Delisting Risk in Annual Report
Sentiment: Negative
View Wiseek Article
BCDA
Mar 17, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
BioCardia's Helix Catheter FDA Pre-Submission Accepted, Advancing Regulatory Pathway
Sentiment: Positive
View Wiseek Article
BCDA
Mar 17, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
FDA Accepts BioCardia's Helix Catheter Pre-Submission, Review Scheduled for Early Q2
Sentiment: Positive
View Wiseek Article
BCDA
Mar 03, 2026, 8:03 AM EST
Source: Wiseek News
Importance Score:
9
BioCardia's Phase III CardiAMP HF Trial Reports Positive Echo Results, Showing Reduced Ventricular Remodeling
Sentiment: Positive
View Wiseek Article
BCDA
Mar 03, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
BioCardia Reports Positive Phase III Echocardiography Results for CardiAMP HF Trial
Sentiment: Positive
View Wiseek Article